YOLFTbeta
DiaMedica Therapeutics Inc

DiaMedica Therapeutics Inc

DMAC · NASDAQ · Healthcare / Biotechnology

8.79USD-0.54 (-5.79%)

Price History

Full chart

Market Stats

Previous Close9.33
Open9.22
Day Range8.11 – 9.22
52-Week Range5.25 – 10.42
Volume214.09K
Market Cap428.17M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.72
Dividend Yield0.00%
Beta0.97
50-Day Avg6.75
200-Day Avg7.12

About

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction. The company develops DM300, which is a recombinant human ulinastatin in the preclinical stage for the treatment of inflammatory diseases, such as acute pancreatitis. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Dietrich John Pauls MBA
  • Employees35
  • Headquarters301 Carlson Parkway, Minneapolis, MN, United States, 55305, USA
  • Websitehttps://www.diamedica.com

Leadership

  • Mr. Dietrich John Pauls MBAPresident, CEO & Director · b. 1971
  • Mr. Scott Kellen CPACFO & Corporate Secretary · b. 1965
  • Dr. Julie Krop M.D.Chief Medical Officer · b. 1966
  • Dr. Ambarish Shah Ph.D.Chief Technology Officer
  • Mr. Dominic R. CundariChief Commercial Officer · b. 1951

Financials

Income Statement

Currency: USD2004-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue33.88K25.68K25.74K160.62K--00000000500.00K0000000
Growth (%)--24.21%+0.23%+524.09%------------100.00%------
Cost of Revenue------000004.46K2.21K4.00K021.00K21.00K24.00K25.00K30.00K39.00K-
Gross Profit33.88K25.68K25.74K160.62K--00000-4.46K-2.21K-4.00K500.00K-21.00K-21.00K-24.00K-25.00K-30.00K-39.00K-
Gross Margin100.00%100.00%100.00%100.00%----------100.00%-------
Operating Expense637.31K228.69K812.95K2.47M--3.84M6.71M10.11M7.43M4.83M1.30M2.48M4.51M7.26M11.57M12.68M13.62M13.98M21.24M26.64M-
Operating Income-603.43K-203.01K-787.21K-2.31M-1.69M-2.40M-3.84M-6.71M-10.11M-7.43M-4.83M-1.31M-2.48M-4.52M-6.76M-11.59M-12.70M-13.65M-14.00M-21.27M-26.68M-34.40M
Operating Margin-1781.04%-790.56%-3058.67%-1438.05%-----------1352.20%-------
EBITDA-630.30K-190.26K-783.89K-2.29M-2.34M-2.27M-3.32M-4.51M-7.70M-6.51M-5.01M-1.50M-2.15M-4.26M-5.64M-11.57M-12.68M-13.54M-13.62M-19.31M-24.38M-32.70M
EBITDA Margin-1860.33%-740.90%-3045.78%-1426.62%-----------1127.80%-------
Net Income-640.02K-210.60K-778.02K-2.33M-1.85M-2.44M-4.27M-6.61M-10.05M-7.41M-4.82M-1.44M-2.22M-4.26M-5.73M-10.65M-12.29M-13.59M-13.68M-19.38M-24.44M-32.77M
Net Income Margin-1889.02%-820.13%-3022.96%-1452.78%-----------1146.80%-------
R&D462.00K22.75K617.26K1.07M1.04M1.37M803.98K2.33M5.21M3.78M3.71M886.07K1.76M3.21M4.52M7.90M8.21M8.77M7.84M13.11M19.06M24.61M
R&D as % of Total Revenue1363.58%88.60%2398.33%664.40%----------904.40%-------
Interest Expense36.59K7.60K0000012.57K2.72K7.73K043.95K48.38K00119.00K229.00K82.00K353.00K---
Interest Expense % of Total Revenue107.99%29.58%0.00%0.00%----------0.00%-------

Balance Sheet

Currency: USD2004-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets216.33K562.60K706.86K4.34M3.00M1.25M9.08M6.33M3.85M2.91M281.59K222.41K1.87M1.80M18.34M9.05M28.09M45.55M34.40M54.16M46.34M61.37M
Total Liabilities1.28M56.49K53.27K272.38K218.01K197.87K554.10K364.56K1.58M1.52M1.81M1.45M626.97K1.00M1.31M1.44M2.08M1.53M2.57M3.10M5.63M5.26M
Total Equity-1.06M506.11K653.59K4.06M2.78M1.05M8.52M5.96M2.26M1.38M-1.53M-1.23M1.25M799.00K17.02M7.62M26.01M44.02M31.83M51.06M40.72M56.11M
Cash7.64K274.76K269.60K3.50M2.47M629.53K2.84M2.65M2.34M2.52M203.78K165.69K1.74M1.35M16.82M3.88M7.41M4.71M4.73M4.54M3.02M15.65M
Total Debt168.18K----------649.21K200.46K-23.00K178.00K118.00K52.00K469.00K400.00K340.00K240.00K
Net Debt160.54K-274.76K-269.60K-3.50M-2.47M-629.53K-2.84M-2.65M-2.34M-2.52M-203.78K483.51K-1.54M-1.35M-16.80M-3.71M-7.29M-4.66M-4.26M-4.14M-2.69M-15.41M

Cash Flow

Currency: USD2004-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-99.35K-831.17K-801.16K-1.21M-1.47M-2.15M-2.38M-3.44M-5.48M-5.50M-3.76M-1.37M-3.02M-3.90M-5.70M-9.10M-9.19M-12.25M-11.51M-18.73M-22.08M-29.06M
Investing Cash Flow-103.46K-76.99K-108.89K-296.17K-85.26K-92.09K-57.61K-79.31K-63.37K-134.27K-31.33K-5.39K-6.89K-22.00K-50.00K-3.91M-16.13M-20.54M11.54M-18.30M8.56M-2.19M
Financing Cash Flow159.51K1.18M905.88K4.69M1.17M-4.61M3.39M5.17M5.97M1.68M1.37M4.59M3.54M21.22M70.00K28.84M30.09M-6.00K36.84M11.99M43.88M
Capital Expenditure103.46K76.99K108.89K296.17K85.26K92.09K57.76K79.31K63.37K134.27K31.33K5.39K6.89K22.00K50.00K2.00K47.00K22.00K81.00K24.00K25.00K40.00K
Free Cash Flow-202.82K-908.15K-910.05K-1.51M-1.55M-2.24M-2.43M-3.52M-5.55M-5.64M-3.79M-1.37M-3.03M-3.92M-5.75M-9.10M-9.23M-12.27M-11.59M-18.75M-22.10M-29.10M
Dividends Paid------000000000-------
FCF to OCF204.14%109.26%113.59%124.41%105.81%104.29%102.43%102.31%101.16%102.44%100.83%100.39%100.23%100.56%100.88%100.02%100.51%100.18%100.70%100.13%100.11%100.14%
Dividend Paid to FCF------0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%-------

Earnings

Report DateSep 30, 2012Dec 31, 2012Mar 31, 2013Aug 28, 2013Nov 28, 2013May 29, 2014Aug 28, 2014Nov 28, 2014May 28, 2015Aug 31, 2015Nov 30, 2015May 27, 2016Aug 29, 2016Nov 29, 2016Apr 27, 2017Aug 29, 2017Nov 27, 2017Apr 30, 2018Aug 29, 2018Nov 18, 2018Mar 19, 2019May 13, 2019Aug 13, 2019Nov 13, 2019Mar 23, 2020May 13, 2020Aug 11, 2020Nov 4, 2020Mar 10, 2021May 5, 2021Aug 11, 2021Nov 10, 2021Mar 14, 2022May 4, 2022Aug 10, 2022Nov 9, 2022Mar 28, 2023May 15, 2023Aug 14, 2023Nov 13, 2023Mar 19, 2024May 8, 2024Aug 7, 2024Nov 13, 2024Mar 17, 2025May 13, 2025Aug 12, 2025Nov 12, 2025Mar 31, 2026May 6, 2026Aug 10, 2026Nov 11, 2026
EPS Estimate------0.54-0.56-0.20-------0.16-0.14-0.16-0.16-0.16-0.16-0.20-0.20-0.26-0.21-0.25-0.28-0.13-0.15-0.17-0.22-0.22-0.23-0.18-0.21-0.18-0.15-0.14-0.16-0.18-0.13-0.14-0.16-0.16-0.15-0.17-0.18-0.19-0.16-0.17-0.18-0.19-0.20
EPS Actual-1.02-1.25-1.08-0.80-0.47-0.74-0.37-0.40-0.14-0.10-0.07-0.08-0.12-0.200.20-0.20-0.17-0.20-0.60-0.07-0.23-0.27-0.21-0.20-0.21-0.19-0.17-0.19-0.23-0.19-0.17-0.18-0.11-0.13-0.13-0.12-0.14-0.20-0.16-0.12-0.14-0.14-0.13-0.15-0.18-0.18-0.18-0.17-0.17-0.19-0.19-
Surprise------37.04%33.93%-100.00%------225.00%-42.86%-6.25%-25.00%-275.00%56.25%-15.00%-35.00%19.23%4.76%16.00%32.14%-30.77%-26.67%-35.29%13.64%22.73%21.74%38.89%38.10%27.78%20.00%0.00%-25.00%11.11%7.69%0.00%12.50%18.75%0.00%-4.35%0.00%5.26%-6.25%2.86%-5.56%0.00%-
Timing-----After-hoursAfter-hours-After-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hours

Key Statistics & Ratios

Market Cap428.17M
Enterprise Value364.36M
Trailing P/E0.00
Forward P/E0.00
Price / Sales66.68
Price / Book10.95
EPS-0.72
Book Value0.711
Revenue (TTM)0
Gross Profit (TTM)0
EBITDA-39.17M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-114.62%
Return on Assets-64.12%
Shares Outstanding53.93M
Shares Float25.30M
Beta0.97
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 4 analystsTarget 15.50
  • Strong Buy
    3
  • Buy
    1

Ownership Breakdown

Institutions
40.91%
Insiders
27.83%
Retail / Other
31.26%

Top Institutional Holders

  • Cooperman Leon G
    3.45M6.40%
  • BlackRock Inc
    1.86M3.44%
  • PARAGON Assoc & PARAGON Assoc II JV
    875.00K1.62%
  • Millennium Management LLC
    845.31K1.57%
  • Geode Capital Management, LLC
    780.52K1.45%
  • State Street Corp
    644.21K1.19%
  • First Manhattan Co. LLC
    455.00K0.84%
  • Bleichroeder LP
    382.32K0.71%
  • Northern Trust Corp
    338.53K0.63%
  • Vanguard Capital Management, LLC
    333.46K0.62%
  • Advisor Group Holdings, Inc.
    319.68K0.59%
  • LPL Financial Corp
    226.05K0.42%
  • Vanguard Portfolio Management, LLC
    203.46K0.38%
  • Vanguard Fiduciary Trust Co
    187.72K0.35%
  • Citadel Advisors Llc
    145.87K0.27%

Top Fund Holders

  • iShares Russell 2000 ETF
    919.29K1.70%
  • Fidelity Small Cap Index
    398.55K0.74%
  • iShares Russell 2000 Growth ETF
    346.78K0.64%
  • Vanguard Russell 2000 ETF
    209.87K0.39%
  • Fidelity Extended Market Index
    156.22K0.29%

Stock Splits

  • Nov 15, 20181:20